Phase 1 Atopic Dermatitis (AD) Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Phase 1 Study of GS101 Injection
Atopic Dermatitis (AD)
Jiangsu Genscend Biopharmaceutical Co., Ltd294 enrolled1 locationNCT07411755
Recruiting
Phase 1
Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis
Atopic Dermatitis (AD)
Good Molecules, LLC36 enrolled1 locationNCT07146971
Recruiting
Phase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
EczemaAtopic Dermatitis (AD)
Arcutis Biotherapeutics, Inc.125 enrolled1 locationNCT07453602
Recruiting
Phase 1
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Atopic Dermatitis (AD)
Daniel Kaplan8 enrolled2 locationsNCT06928246
Recruiting
Phase 1
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis (AD)
Jiangsu vcare pharmaceutical technology co., LTD10 enrolled1 locationNCT07329101
Recruiting
Phase 1
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Psoriasis (PsO)Atopic Dermatitis (AD)
LAPIX Therapeutics Inc.48 enrolled3 locationsNCT06982352
Recruiting
Phase 1
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Zai Lab (Shanghai) Co., Ltd.84 enrolled1 locationNCT07235384
Recruiting
Phase 1
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Atopic Dermatitis (AD)Normal Volunteers
Attovia Therapeutics Inc72 enrolled1 locationNCT07205081
Active
Phase 1
A Phase 1, First in Human, Randomised, Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Investigate the Safety, Tolerability and Pharmacokinetics of GB-7624 administered subcutaneously in Healthy Adult participants
EczemaAtopic Dermatitis (AD)
Generate Biomedicines Inc.40 enrolled1 locationACTRN12625000229471